The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Unravelling the biology of SCLC: implications for therapy
Open accessAbstract
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor prognosis. First-line treatment has remained unchanged for decades, and a paucity of effective treatment options exists for recurrent disease. Nonetheless, advances in our understanding of SCLC biology have led to the development of novel experimental therapies. Poly [ADP-ribose] polymerase (PARP) inhibitors have shown promise in preclinical models, and are under clinical investigation in combination with cytotoxic therapies and inhibitors of cell-cycle checkpoints.Preclinical data indicate that targeting of histone-lysine N-methyltransferase EZH2, a regulator of chromatin remodelling implicated in acquired therapeutic resistance, might augment and prolong chemotherapy responses. High expression of the inhibitory Notch ligand Delta-like protein 3 (DLL3) in most SCLCs has been linked to expression of Achaete-scute homologue 1 (ASCL1; also known as ASH-1), a key transcription factor driving SCLC oncogenesis; encouraging preclinical and clinical activity has been demonstrated for an anti-DLL3-antibody–drug conjugate. The immune microenvironment of SCLC seems to be distinct from that of other solid tumours, with few tumour-infiltrating lymphocytes and low levels of the immune-checkpoint protein programmed cell death 1 ligand 1 (PD-L1). Nonetheless, immunotherapy with immune-checkpoint inhibitors holds promise for patients with this disease, independent of PD-L1 status. Herein, we review the progress made in uncovering aspects of the biology of SCLC and its microenvironment that are defining new therapeutic strategies and offering renewed hope for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Comprehensive genomic profiles of small cell lung cancer
George, J., Lim, J. S., Jang, S. J., Cun, Y., Ozretić, L., Kong, G., Leenders, F., Lu, X., Fernández-Cuesta, L., Bosco, G., et al. (2015) · Nature · doi:10.1038/nature14664 · Cited by 2,340
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Linking DNA methylation and histone modification: patterns and paradigms
Cedar, H., & Bergman, Y. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2540 · Cited by 2,267
Travis, W. D., Brambilla, E., Burke, A. P., Marx, A., & Nicholson, A. G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000663 · Cited by 1,905
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
Aupérin, A., Arriagada, R., Pignon, J.-P., Le Péchoux, C., Gregor, A., Stephens, R. J., Kristjansen, P. E. G., Johnson, B. E., Ueoka, H., Wagner, H., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410703 · Cited by 1,718
WHO classification of tumours of the lung, pleura, thymus and heart
Travis, W. D. (2015) · International Agency for Research on Cancer eBooks · Cited by 1,664
Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., & Johnson, D. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400403 · Cited by 1,506
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer
Pignon, J.-P., Arriagada, R., Ihde, D. C., Johnson, D. H., Perry, M. C., Souhami, R. L., Brodin, O., Joss, R. A., Kies, M. S., Lebeau, B., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272302 · Cited by 1,331
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., & Helin, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg542 · Cited by 1,196
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., Postmus, P., Collette, L., Musat, E., & Senan, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071780 · Cited by 1,133
Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z., Shames, D. S., Bergbower, E. A., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,077
Self-citationThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 903
(1986) · Lung Cancer · doi:10.1016/s0169-5002(86)80023-x · Cited by 900
CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W. A., Xu, H., Peng, H., Fu, Y.-X., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 767
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Mateos-Gomez, P. A., Gong, F., Nair, N., Miller, K. M., Lazzerini-Denchi, E., & Sfeir, A. (2015) · Nature · doi:10.1038/nature14157 · Cited by 765
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours
Esteller, M., & Herman, J. G. (2002) · The Journal of Pathology · doi:10.1002/path.1024 · Cited by 743
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Inactivation of the p34 cdc2 -Cyclin B Complex by the Human WEE1 Tyrosine Kinase
Parker, L. L., & Piwnica-Worms, H. (1992) · Science · doi:10.1126/science.1384126 · Cited by 716
Hanna, N., Bunn, P. A., Langer, C., Einhorn, L., Guthrie, T., Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8595 · Cited by 681
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654
Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643
Mishima, S., Nozaki, Y., Mikami, S., Kihira, E., Iikura, M., Koketsu, R., Sugiyama, H., Masuda, T., Kaname, H., Egami, Y., et al. (2015) · Case Reports in Gastroenterology · doi:10.1159/000381140 · Cited by 631
Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 611
Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., Keijser, A., Faivre-Finn, C., & Senan, S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61085-0 · Cited by 604
Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R., Escarpe, P. A., Hampl, J., Laysang, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9459 · Cited by 600
Self-citationMollaoglu, G., Guthrie, M. R., Böhm, S., Brägelmann, J., Can, I., Ballieu, P. M., Marx, A., George, J., Heinen, C., Chalishazar, M. D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.005 · Cited by 588
Rudin, C. M., Pietanza, M. C., Bauer, T. M., Ready, N., Morgensztern, D., Glisson, B. S., Byers, L. A., Johnson, M. L., Burris, H. A., Robert, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30565-4 · Cited by 574
Self-citationRossi, A., Di Maio, M., Chiodini, P., Rudd, R. M., Okamoto, H., Skarlos, D. V., Früh, M., Qian, W., Tamura, T., Samantas, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4905 · Cited by 570
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
Roth, B. J., Johnson, D. H., Einhorn, L. H., Schacter, L. P., Cherng, N. C., Cohen, H. J., Crawford, J., Randolph, J. A., Goodlow, J. L., & Broun, G. O. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.282 · Cited by 556
Takahashi, T., Yamanaka, T., Seto, T., Harada, H., Nokihara, H., Saka, H., Nishio, M., Kaneda, H., Takayama, K., Ishimoto, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30230-9 · Cited by 549
Hirai, H., Iwasawa, Y., Okada, M., Arai, T., Nishibata, T., Kobayashi, M., Kimura, T., Kaneko, N., Ohtani, J., Yamanaka, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0463 · Cited by 540
Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 538
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Gardner, E. E., Lok, B. H., Schneeberger, V. E., Desmeules, P., Miles, L. A., Arnold, P. K., Ni, A., Khodos, I., de Stanchina, E., Nguyen, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.006 · Cited by 526
Self-citationLara, P. N., Natale, R., Crowley, J., Lenz, H. J., Redman, M. W., Carleton, J. E., Jett, J., Langer, C. J., Kuebler, J. P., Dakhil, S. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1061 · Cited by 525
Pesch, B., Kendzia, B., Gustavsson, P., Jöckel, K., Johnen, G., Pohlabeln, H., Olsson, A., Ahrens, W., Gross, I. M., Brüske, I., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27339 · Cited by 509
Self-citationBorromeo, M. D., Savage, T. K., Kollipara, R. K., He, M., Augustyn, A., Osborne, J. K., Girard, L., Minna, J. D., Gazdar, A. F., Cobb, M. H., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.081 · Cited by 503
Vallières, E., Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., Chansky, K., Shaikh, Z., & Goldstraw, P. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181b27799 · Cited by 488
Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P., Giaccone, G., Schaefer, B., Wanders, J., & Verweij, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2090 · Cited by 480
Gazdar, A. F., Carney, D. N., Nau, M. M., & Minna, J. D. (1985) · PubMed · Cited by 477
Functions and molecular mechanisms of the CD47–SIRPα signalling pathway
Matozaki, T., Murata, Y., Okazawa, H., & Ohnishi, H. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.12.001 · Cited by 475
Fukuoka, M., Furuse, K., Saijo, N., Nishiwaki, Y., Ikegami, H., Tamura, T., Shimoyama, M., & Suemasu, K. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.12.855 · Cited by 456
An achaete-scute homologue essential for neuroendocrine differentiation in the lung
Borges, M., Linnoila, R. I., van de Velde, H. J. K., Chen, H., Nelkin, B. D., Mabry, M., Baylin, S. B., & Ball, D. W. (1997) · Nature · doi:10.1038/386852a0 · Cited by 454
Aurora A kinase (AURKA) in normal and pathological cell division
Nikonova, A. S., Astsaturov, I., Serebriiskii, I. G., Dunbrack, R. L., & Golemis, E. A. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1073-7 · Cited by 448
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Weiskopf, K., Jahchan, N. S., Schnorr, P. J., Cristea, S., Ring, A. M., Maute, R. L., Volkmer, A. K., Volkmer, J.-P., Liu, J., Lim, J. S., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81603 · Cited by 444
Self-citationNicholson, A. G., Chansky, K., Crowley, J., Beyruti, R., Kubota, K., Turrisi, A., Eberhardt, W. E. E., van Meerbeeck, J., Rami-Porta, R., Goldstraw, P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.008 · Cited by 421
Targeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408
Ito, T., Udaka, N., Yazawa, T., Okudela, K., Hayashi, H., Sudo, T., Guillemot, F., Kageyama, R., & Kitamura, H. (2000) · Development · doi:10.1242/dev.127.18.3913 · Cited by 404
de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 387
Girard, L., Zöchbauer‐Müller, S., Virmani, A. K., Gazdar, A. F., & Minna, J. D. (2000) · PubMed · Cited by 352
Lok, B. H., Gardner, E. E., Schneeberger, V. E., Ni, A., Desmeules, P., Rekhtman, N., de Stanchina, E., Teicher, B. A., Riaz, N., Powell, S. N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1040 · Cited by 344
Self-citationThe role of EZH2 in tumour progression
Chang, C.-J., & Hung, M.-C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.551 · Cited by 332
Watkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Vyas, S., Chesarone-Cataldo, M., Todorova, T., Huang, Y.-H., & Chang, P. (2013) · Nature Communications · doi:10.1038/ncomms3240 · Cited by 317
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Manfredi, M. G., Ecsedy, J. A., Chakravarty, A., Silverman, L., Zhang, M., Hoar, K. M., Stroud, S. G., Chen, W., Shinde, V., Huck, J. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1536 · Cited by 300
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Murai, J., Feng, Y., Yu, G. K., Ru, Y., Tang, S.-W., Shen, Y., & Pommier, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12266 · Cited by 297
Macrophages are critical effectors of antibody therapies for cancer
Weiskopf, K., & Weissman, I. L. (2015) · mAbs · doi:10.1080/19420862.2015.1011450 · Cited by 292
Ladi, E., Nichols, J. T., Ge, W., Miyamoto, A., Yao, C., Yang, L.-T., Boulter, J., Sun, Y. E., Kintner, C., & Weinmaster, G. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200503113 · Cited by 282
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers
Augustyn, A., Borromeo, M., Wang, T., Fujimoto, J., Shao, C., Dospoy, P. D., Lee, V., Tan, C., Sullivan, J. P., Larsen, J. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410419111 · Cited by 282
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Hopkins-Donaldson, S., Ziegler, A., Kurtz, S., Bigosch, C., Kandioler, D., Ludwig, C., Zangemeister-Wittke, U., & Stahel, R. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401157 · Cited by 270
Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Brambilla, E. M., NEGOESCU, A., Gazzéri, S., Lantuéjoul, S., Moro‐Sibilot, D., Brambilla, C., & Coll, J. (1996) · Europe PMC (PubMed Central) · Cited by 268
Melichar, B., Adenis, A., Lockhart, A. C., Bennouna, J., Dees, E. C., Kayaleh, O., Obermannova, R., DeMichele, A., Zatloukal, P., Zhang, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70051-3 · Cited by 254
Poirier, J. T., Gardner, E. E., Connis, N., Moreira, A. L., de Stanchina, E., Hann, C. L., & Rudin, C. M. (2015) · Oncogene · doi:10.1038/onc.2015.38 · Cited by 248
Self-citationDevelopment of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V., Chin, K., Canetta, R., & Humphrey, R. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.015 · Cited by 242
Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.7.11115 · Cited by 237
Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)
Antonow, D., & Thurston, D. E. (2011) · Chemical Reviews · doi:10.1021/cr100120f · Cited by 235
Lok, B. H., Carley, A. C., Tchang, B., & Powell, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.391 · Cited by 215
Self-citationMorimoto, M., Nishinakamura, R., Saga, Y., & Kopan, R. (2012) · Development · doi:10.1242/dev.083840 · Cited by 213
Chapman, G., Sparrow, D. B., Kremmer, E., & Dunwoodie, S. L. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq529 · Cited by 196
Exclusion of Kaposi Sarcoma From Analysis of Cancer Burden—Reply
Fitzmaurice, C., & Naghavi, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1747 · Cited by 189
Niell, H. B., Herndon, J. E., Miller, A. A., Watson, D. M., Sandler, A. B., Kelly, K., Marks, R. S., Perry, M. C., Ansari, R. H., Otterson, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.071 · Cited by 187
Jiang, T., Collins, B. J., Jin, N., Watkins, D. N., Brock, M. V., Matsui, W., Nelkin, B. D., & Ball, D. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2762 · Cited by 186
Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors
Kunnimalaiyaan, M., & Chen, H. (2007) · The Oncologist · doi:10.1634/theoncologist.12-5-535 · Cited by 186
Petersen, I., Langreck, H., Wolf, G., Schwendel, A., Psille, R., Vogt, P., Reichel, M., Ried, T., & Dietel, M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.13 · Cited by 181
Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
Guertin, A. D., Li, J., Liu, Y., Hurd, M. S., Schuller, A. G., Long, B., Hirsch, H. A., Feldman, I., Benita, Y., Toniatti, C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0025 · Cited by 172
Nogales, V., Reinhold, W. C., Varma, S., Martinez-Cardus, A., Moutinho, C., Moran, S., Heyn, H., Sebio, A., Barnadas, A., Pommier, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6413 · Cited by 169
SLFN11 inhibits checkpoint maintenance and homologous recombination repair
Mu, Y., Lou, J., Srivastava, M., Zhao, B., Feng, X., Liu, T., Chen, J., & Huang, J. (2016) · The EMBO Reports · doi:10.15252/embr.201540964 · Cited by 160
Yu, H., Batenchuk, C., Badzio, A., Boyle, T. A., Czapiewski, P., Chan, D. C. F., Lu, X. J. D., Gao, D., Ellison, K. E., Kowalewski, A. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.002 · Cited by 145
Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes
Varghese, A. M., Zakowski, M. F., Yu, H. A., Won, H. H., Riely, G. J., Krug, L. M., Kris, M. G., Rekhtman, N., Ladanyi, M., Wang, L., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000142 · Cited by 141
Fujino, K., Motooka, Y., Hassan, W. A., Abdalla, M. O. A., Sato, Y., Kudoh, S., Hasegawa, K., Niimori‐Kita, K., Kobayashi, H., Kubota, I., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.08.018 · Cited by 138
Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines
Gerratana, B. (2010) · Medicinal Research Reviews · doi:10.1002/med.20212 · Cited by 136
Selective Tropism of Seneca Valley Virus for Variant Subtype Small Cell Lung Cancer
Poirier, J. T., Dobromilskaya, I., Moriarty, W. F., Peacock, C. D., Hann, C. L., & Rudin, C. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt130 · Cited by 133
Self-citationLinden, A. A. V., Baturin, D., Ford, J. B., Fosmire, S. P., Gardner, L. A., Korch, C. T., Reigan, P., & Porter, C. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0424 · Cited by 130
Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years
Gaspar, L. E., McNamara, E. J., Gay, E. G., Putnam, J. B., Crawford, J., Herbst, R. S., & Bonner, J. A. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.05.008 · Cited by 124
ASH1 Gene Is a Specific Therapeutic Target for Lung Cancers with Neuroendocrine Features
Osada, H., Tatematsu, Y., Yatabe, Y., Horio, Y., & Takahashi, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1404 · Cited by 123
Gazdar, A. F., Savage, T. K., Johnson, J. E. B., Berns, A. J. M., Sage, J., Linnoila, R. I., MacPherson, D. P., McFadden, D. G., Farago, A. F., Jacks, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000459 · Cited by 123
Karlsson, A., Jönsson, M., Lauss, M., Brunnström, H., Jönsson, P., Borg, Å., Jönsson, G. B., Ringnér, M., Planck, M., & Staaf, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1087 · Cited by 119
Transcriptional gene expression profiling of small cell lung cancer cells.
Pedersen, N. M., Mortensen, S., Sørensen, S. B., Pedersen, M. W., Rieneck, K., Bovin, L. F., & Poulsen, H. S. (2003) · PubMed · Cited by 117
Simbulan-Rosenthal, C. M., Rosenthal, D. S., Luo, R., Samara, R. N., Espinoza, L. A., Hassa, P. O., Hottiger, M. O., & Smulson, M. E. (2003) · Oncogene · doi:10.1038/sj.onc.1206897 · Cited by 115
Lok, B. H., & Powell, S. N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3150 · Cited by 110
Self-citationSLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma
Tang, S.-W., Bilke, S., Cao, L., Murai, J., Sousa, F. G., Yamade, M., Rajapakse, V. N., Varma, S., Helman, L. J., Khan, J. I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2112 · Cited by 106
myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines
Johnson, B. E. (1989) · Lung Cancer · doi:10.1016/0169-5002(89)90322-x · Cited by 101
Coe, B. P., Thu, K. L., Aviel‐Ronen, S., Vucic, E. A., Gazdar, A. F., Lam, S. C., Tsao, M., & Lam, W. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071670 · Cited by 99
Shivapurkar, N., Virmani, A. K., Wistuba, I. I., Milchgrub, S., Mackay, B., Minna, J. D., & Gazdar, A. F. (1999) · PubMed · Cited by 95
Kalari, S. K., Jung, M., Kernstine, K. H., Takahashi, T., & Pfeifer, G. P. (2012) · Oncogene · doi:10.1038/onc.2012.362 · Cited by 92
Clinical correlation of extensive-stage small-cell lung cancer genomics
Dowlati, A., Lipka, M. B., McColl, K. S., Dabir, S., Behtaj, M., Kresak, A. M., Miron, A., Yang, M., Sharma, N., Fu, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw005 · Cited by 88
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Mesa, R. A., Jamieson, C. H. M., Bhatia, R., Deininger, M. W., Gerds, A. T., Gojo, I., Gotlib, J. R., Gundabolu, K., Hobbs, G. S., Klisovic, R. B., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0169 · Cited by 76
Kaminskyy, V. O., Surova, O. V., Vaculová, A. H., & Zhivotovsky, B. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr135 · Cited by 72
Tamborini, E., Bonadiman, L., Negri, T., Greco, A., Staurengo, S., Bidoli, P., Pastorino, U., Pierotti, M. A., & Pilotti, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1013 · Cited by 67
Loomes, K. M., Stevens, S. A., O’Brien, M. L., Gonzalez, D. M., Ryan, M. J., Segalov, M., Dormans, N. J., Mimoto, M. S., Gibson, J. D., Sewell, W., et al. (2007) · Developmental Dynamics · doi:10.1002/dvdy.21296 · Cited by 52
Lok, B. H., Ma, J., Foster, A., Perez, C. A., Shi, W., Zhang, Z., Li, B. T., Rudin, C. M., Rimner, A., & Wu, A. J.-C. (2017) · Advances in Radiation Oncology · doi:10.1016/j.adro.2017.08.001 · Cited by 47
Self-citationDeng, Y., Cai, Y., Huang, Y. J., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1840-6 · Cited by 43
Lu, Y., Liu, Y., Jiang, J., Xi, Z., Zhong, N., Shi, S., Wang, J., & Wei, X. (2014) · Oncology Reports · doi:10.3892/or.2014.3194 · Cited by 40
Wang, Y., Long, Y., Xu, Y., Guan, Z., Lian, P., Peng, J., Cai, S., & Cai, G. (2014) · Gastroenterology Research and Practice · doi:10.1155/2014/436985 · Cited by 24
Saito, Y., Nagae, G., Motoi, N., Miyauchi, E., Ninomiya, H., Uehara, H., Mun, M., Okumura, S., Ohyanagi, F., Nishio, M., et al. (2016) · Cancer Science · doi:10.1111/cas.12876 · Cited by 24
Byers, L. A., Krug, L. M., Waqar, S. N., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Bensman, Y., Hurtado, B. Y., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.466 · Cited by 16
Self-citation
Cited by
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Rudin, C. M., Poirier, J. T., Byers, L. A., Dive, C., Dowlati, A., George, J., Heymach, J. V., Johnson, J. E., Lehman, J. M., MacPherson, D., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0133-9 · Cited by 1,254
Self-citationNotch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Burr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 649
Baine, M. K., Hsieh, M.-S., Lai, W. V., Egger, J. V., Jungbluth, A. A., Daneshbod, Y., Beras, A., Spencer, R., Lopardo, J., Bodd, F., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.009 · Cited by 522
Self-citationChan, J. M., Quintanal-Villalonga, Á., Gao, V. R., Xie, Y., Allaj, V., Chaudhary, O., Masilionis, I., Egger, J., Chow, A., Walle, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.008 · Cited by 434
Self-citation
Metadata
- Authors
- Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-05-23
- Volume
- 14
- Issue
- 9
- Pages
- 549-561
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2617007913
- Cited by
- 490
- References
- 140
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.